Drug invoice shortage findings: the 30-day window most pharmacies miss

A Drug Invoice Shortage finding — usually abbreviated as DIS in PBM correspondence — is one of the fastest-escalating audit patterns independent pharmacies face. The underlying logic is simple: the PBM adds up the quantity of a specific medication you billed during a review period, then asks whether your purchase invoices for that same period show enough inventory to have supported those claims. If the answer is no, the gap is treated as an overpayment.

The finding sounds like a reasonable inventory check. In practice, it is almost always resolvable. The reason most DIS findings stand is that pharmacies misunderstand the review window, the acceptable purchase sources, and the documentation standards — all of which are narrower than typical record-retention assumes.

The 30-day rule most pharmacies miss

Most major PBM provider manuals define the drug invoice review window as 30 days surrounding the audit period. Some use slightly longer windows — 45 or 60 days — but 30 is the most common standard.

This matters because independent pharmacies typically maintain inventory with a 60 to 90 day turnover cycle. You might purchase a bottle of medication in January, dispense from it through March, and record the last claim in early April. If the PBM audits the March claims, their 30-day review window starts in mid-February and ends in mid-March — which means the original January invoice falls outside the review window.

The dispensing was legitimate. The purchase was legitimate. But the paperwork for the purchase is outside the window the PBM will consider. That is how DIS findings get generated against completely compliant operations.

What counts as a valid purchase record

PBM provider manuals distinguish between wholesaler purchases and alternative acquisition sources. The distinction matters significantly in how you document.

Primary wholesaler purchases. These are the easiest to document. Invoices from authorized distributors like McKesson, Cardinal Health, AmerisourceBergen, or similar wholesalers generally satisfy documentation requirements when they include the NDC, quantity, date, and purchase order reference.

Secondary wholesaler purchases. Same format as primary wholesalers, but some PBMs require explicit disclosure that the purchase was from a secondary source, particularly for high-cost medications. Always check the provider manual for specific language about secondary sourcing.

Pharmacy-to-pharmacy transfers. This is where most DIS findings become unsalvageable. Under the Drug Supply Chain Security Act (DSCSA), pharmacy-to-pharmacy transfers require three separate documents: Transaction Statement, Transaction History, and Transaction Information. A simple purchase receipt or internal transfer memo is not sufficient. Most independent pharmacies do not maintain all three consistently, and PBMs reject documentation that lacks any one of them.

Manufacturer direct purchases. Generally acceptable when documented with standard invoice format, but some PBMs require additional verification for high-cost or specialty medications.

Why secondary wholesaler documentation trips up so many audits

When primary wholesalers run out of a medication, independent pharmacies often source from secondary wholesalers to maintain dispensing continuity. This is legal, appropriate, and in many cases the only way to keep patients on their medications during shortages.

The documentation challenge is that secondary wholesaler invoices often lack the clean transaction-history format that PBMs expect. Without a full Transaction Statement under DSCSA, a secondary wholesaler invoice may be treated as incomplete — even though the purchase itself was compliant. Some PBMs will accept a supplementary letter from the secondary wholesaler confirming DSCSA compliance, but this needs to be requested proactively during the appeal window.

The window tightens with high-cost medications

For specialty medications, Schedule II controlled substances, and drugs on PBM audit watchlists, review windows can be narrower than the standard 30 days, and documentation standards are stricter. Some major PBMs apply a 14-day window for specialty drug claims and require contemporaneous delivery logs in addition to purchase invoices.

If a DIS finding involves a specialty drug, check the specific provider manual section for specialty dispensing before applying the standard 30-day logic. The two frameworks are often not the same.

Building documentation that survives DIS audits

Three practices reduce DIS exposure substantially over time. First, maintain complete DSCSA transaction records for every non-wholesaler acquisition source, including pharmacy-to-pharmacy transfers and manufacturer direct purchases. Second, reconcile your dispensing claims against your inventory records monthly, not quarterly — the misalignment between claim periods and invoice periods is easier to catch in short windows. Third, retain purchase records for at least 10 years, even after the PBM review window closes, because network termination proceedings sometimes reach back further than standard audit windows.

None of this prevents DIS findings from being issued. It ensures that when one is issued, you have the documentation structured to respond within the appeal window — which is the only part of the process you fully control.